Literature DB >> 1743241

Effect of lacidipine, a long-acting calcium antagonist, on hypertension and lipids: a 1 year follow-up.

S Soro1, L A Ferrara.   

Abstract

The effect of lacidipine, a dihydropyridine calcium antagonist on lipid metabolism, has been followed in 8 patients with uncomplicated mild to moderate essential hypertension treated for up to 14 months. There were significant reductions in the systolic and diastolic pressures, from 167/102 to 146/91 mm Hg at 2 months, and to 137/85 mm Hg at the end of the study. Blood lipid concentrations did not change during the observation period (cholesterol 5.1 vs 5.3 mmol.l-1, triglycerides 1.1 vs 1.0 mmol.l-1, HDL-cholesterol 1.1 vs 1.2 mmol.l-1). The results show that lacidipine did not affect lipid metabolism and suggest that calcium antagonists may be safely prescribed for a prolonged period to patients with combined hypertension and hyperlipidaemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1743241     DOI: 10.1007/BF00265900

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Letter: Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation.

Authors:  G M Kostner
Journal:  Clin Chem       Date:  1976-05       Impact factor: 8.327

2.  Enhancement of exogenous triglyceride removal following calcium channel blockade.

Authors:  T Marotta; L A Ferrara; F Pasanisi; P Rubba; C Iovine; M Mancini
Journal:  Artery       Date:  1989

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Review of primary prevention trials.

Authors:  G Rose
Journal:  Am Heart J       Date:  1987-10       Impact factor: 4.749

5.  The effects of nicardipine on sodium and calcium metabolism in hypertensive patients: a chronic study.

Authors:  S Soro; A Cocca; F Pasanisi; A Tommaselli; G de Simone; G Costantino; L A Ferrara
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

6.  No metabolic side effects of long-term treatment with verapamil in hypertension.

Authors:  K Midtbø; O Lauve; O Hals
Journal:  Angiology       Date:  1988-12       Impact factor: 3.619

7.  Clinical pharmacological studies on the interaction between alpha-adrenoceptors and calcium antagonists.

Authors:  J L Reid; F Pasanisi; P A Meredith; H L Elliott
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Elevation of serum lipid levels during diuretic therapy of hypertension.

Authors:  R P Ames; P Hill
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

9.  Effects of diltiazem hydrochloride on serum lipids: comparison with beta-blockers.

Authors:  S Wada; M Nakayama; K Masaki
Journal:  Clin Ther       Date:  1982       Impact factor: 3.393

10.  Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Authors:  P Leren; P O Foss; A Helgeland; I Hjermann; I Holme; P G Lund-Larsen
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

View more
  1 in total

Review 1.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.